SEH1L

Across TCGA pan-cancer cohorts, SEH1L mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SEH1L’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SEH1L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SEH1L is over-expressed in tumor.

HNSC, COAD, and LSCC are the cancer types where SEH1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEH1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+0.279	<.001	11	view →
COAD	Male	III,IV	+0.328	<.001	9	view →
LSCC	Male	III,IV	+0.299	<.001	8	view →
LUAD	Male	All	+0.212	<.001	8	view →
CCRCC	Male	III,IV	+0.103	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SEH1L–HNSC

Open the HNSC breakdown →